mutation-based risk stratification approaches in myelofibrosis: any real clinical utility?
Published 8 years ago • 198 plays • Length 13:24Download video MP4
Download video MP3
Similar videos
-
18:38
mutation-based risk stratification approaches in myelofibrosis: any real clinical utility?
-
23:17
mutations in myelofibrosis: which to test for, when and why
-
20:03
my approach to mf management
-
22:06
myelofibrosis prognostic scoring systems: ipss, dipss, dipss-plus, misps, and gipss
-
3:29
case 1: risk stratification models for myelofibrosis
-
22:18
use of molecular genetic testing in mds and mpn
-
7:46
risk stratification in myelofibrosis
-
4:20
primary myelofibrosis: risk stratification
-
9:56
myelofibrosis: diagnosis and risk stratification
-
19:54
therapy for “early myelofibrosis”: pros and cons
-
22:27
influence of mutational status on timing, outcome, and post-transplant management of myelofibrosis
-
4:31
risk stratification for patients with myelofibrosis
-
23:20
therapy for “early mf”: pros and cons
-
1:00
how genomic testing has influenced treatment approaches and clinical trial design in mpns
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
17:43
influence of mutational status on timing, outcome and post-transplant management of myelofibrosis
-
19:11
novel agents and combination therapies in myelofibrosis